Skip to main content
. 2020 Jul 29;55(3):195–206. doi: 10.1097/MCG.0000000000001396

TABLE 3.

AGA-suggested Target Ctrough for Reactive TDM in Patients With Active IBD on Anti-TNF Maintenance Therapy17

Drug Suggested Target Ctrough (µg/mL)
Infliximab ≥5
Adalimumab ≥7.5
Golimumab Unknown
Certolizumab pegol ≥20

AGA indicates American Gastroenterological Association; Ctrough, trough concentration; IBD, inflammatory bowel disease; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor.